Atopic Dermatitis

A study reveals that upadacitinib dose adjustments in atopic dermatitis enhance treatment personalization.

This analysis of patients with atopic dermatitis in the BIOREP registry spotlight the safety and efficacy of lebrikizumab therapy.

Real-world review finds Black patients report fewer dupilumab-related adverse events than White patients.

This list highlights a variety of notable DERM 2025 conference news coverage, specifically in the field of atopic dermatitis.

The PAISLEY CLE trial findings highlight deucravacitinib’s efficacy among patients with cutaneous lupus, including those with concurrent SLE.

This segment of Hebert’s DERM 2025 interview highlights additional conclusions from her team’s data on roflumilast in atopic dermatitis among infants and toddlers.

In a DERM 2025 conference interview, Hebert highlights takeaways from her team’s findings on roflumilast cream in patients aged 3 months to 2 years with atopic dermatitis.

These data were presented at DERM 2025, highlighting recent findings on the impact of tralokinumab on atopic dermatitis.

During this DERM 2025 interview segment, Martinez-Dulay touches on highlights from her sessions in which she explores allergic contact dermatitis.

This interim data was drawn from the TRACE study, highlighting real-world use of tralokinumab in adults with atopic dermatitis of the head and neck.

In a new interview at the DERM2025 Conference, Boswell highlights a session on systemic drugs and another session on wart and molluscum imitators.

In an ADvocate study subpopulation, new findings suggest lebrikizumab therapy leads to significant disease control and positive itch impacts.

FDA approval of topical delgocitinib marks a long-awaited treatment milestone for adults with chronic hand eczema.

FDA approves delgocitinib cream, offering a new treatment option for adults with moderate-to-severe chronic hand eczema.

This analysis examined the connection between atopic dermatitis severity and frequency of flares, along with which variables potentially predict flares.

Panelists discuss how to effectively onboard patients to Janus kinase (JAK) inhibitors through transparent risk discussions, early follow-up visits at 4 weeks, and personalized treatment approaches that consider patient-reported outcomes and the “3 Cs” (cancer, cardiac disease, clotting disease) while emphasizing the anti-inflammatory benefits and quality-of-life improvements these therapies provide.

Panelists discuss how Janus kinase (JAK) inhibitors demonstrate a favorable safety profile across age groups and comorbid populations, with potential cardioprotective benefits due to their anti-inflammatory effects, while addressing common concerns about the boxed warning by emphasizing that only herpes zoster reactivation, tuberculosis, and nonmelanoma skin cancer show increased rates across all indications.

Panelists discuss how abrocitinib demonstrated superior efficacy compared with dupilumab in head-to-head trials, with 77% of dupilumab nonresponders achieving Eczema Area and Severity Index 75 (EASI-75) after switching to abrocitinib for 12 weeks, supported by real-world registry data showing consistent outcomes across diverse patient populations.

Panelists discuss how the Level Up study demonstrated that patients who didn’t achieve Eczema Area and Severity Index 75 (EASI-75) on dupilumab could be successfully switched to upadacitinib without washout, with two-thirds achieving EASI-75 and one-third achieving EASI-90 within just 4 weeks of switching.

Panelists discuss how switching from biologics to Janus kinase (JAK) inhibitors should be considered when patients don’t achieve adequate disease control within 3 to 6 months, experience tolerability issues, or continue to have significant quality-of-life impacts despite apparent skin improvement.

Panelists discuss how oral Janus kinase (JAK) inhibitors offer advantages over biologics in specific clinical scenarios including patients needing rapid onset of action, those with comorbid arthralgia, head and neck involvement, needle fatigue, and environmental trigger sensitivity due to their broad anti-inflammatory effects.

Panelists discuss how the AHEAD recommendations establish evidence-based treatment targets requiring simultaneous achievement of skin clearance (Eczema Area and Severity Index [EASI]-90) and itch relief (itch score 0-1) within 3 to 6 months, fundamentally changing the standard of care by incorporating patient-reported outcomes alongside physician assessments.

Panelists discuss how Janus kinase (JAK) inhibitors represent a revolutionary advancement in atopic dermatitis treatment by targeting multiple cytokine pathways simultaneously at the intracellular level, offering broader therapeutic coverage than biologics that target only 1 or 2 specific cytokines.

These ADHAND trial data highlight the results of tralokinumab in those with atopic dermatitis on the hands who are candidates for systemic therapy.

Phase 3 trials have shown low rates of serious adverse events with ruxolitinib cream in pediatric and adult patients with atopic dermatitis and non-segmental vitiligo.